In this analysis of the phase 3 ALLTO trial, researchers explored 10-year outcomes of HR+, HER2+ early breast cancer patients who received either an aromatase inhibitor or a selective estrogen ...
Selective estrogen receptor modulators (SERMs) are medications that can both mimic and block estrogen’s effects in different tissues. They do this by interacting with estrogen receptors in different ...
April 21, 2010 (Washington, DC) — Long-term data from the landmark Study of Raloxifene and Tamoxifen (STAR) confirm that both drugs reduce the risk for breast cancer. "There is no longer any doubt ...
September 17, 2008 (Montreal, Quebec) — An investigational new selective estrogen-receptor modulator (SERM) is showing promise in the treatment of osteoporosis among postmenopausal women, according to ...
As per DelveInsight's analysis, the total market size of SERM in the 7MM is expected to surge significantly by 2034. The report provides the total potential number of patients in the indications, such ...
Selective estrogen receptor modulators (SERMs) hold the promise of an ideal estrogenic compound. Moderate efficacy for the prevention of osteoporotic vertebral fractures has now been found after 5 ...
The cardioprotective effects of estrogen are mediated by receptors expressed in vascular cells. Here we show that 27-hydroxycholesterol (27HC), an abundant cholesterol metabolite that is elevated with ...
A novel approach for 21-genes testing associated with prognosis in Chinese patients with ER-positive/HER2-negative breast cancer: A real-world study. This is an ASCO ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback